トップページ業 績 > 論文発表 2016年

2016年 論文発表

<英文> 16論文

  1. Kubota Y, Nakaigawa N; Committee for Establishment of the Clinical Practice Guideline for the Management of Bladder Cancer and the Japanese Urological Association:Nishiyama H, Hinotsu S, Ogawa O, Inoue K, Ozono S, Kikuchi E, Miki T, Matsuyama H, Fujioka T, Ohyama C, Fujimoto H, Azuma H, Habuchi T, Nakagawa M, Mizowaki T, Matsui Y, Kobayashi T, Osaka K, Furuse H, Naya Y, Obara W, Koike T, Yoneyama T, Hashimoto Y, Hatakeyama S, Imai A, Nakanishi H, Hara T, Tsuchiya N, Inoue T, Ohta J, Suzuki K, Fujikawa A, Umemoto S, Izumi K, Noguchi S.
    Essential content of evidence-based clinical practice guidelines for bladder cancer: The Japanese Urological Association 2015 update.
    Int J Urol. 2016 Aug;23(8):640-5. doi: 10.1111/iju.13141. Epub 2016 Jul 3.
  2. Oh JS, Strudwick X, Short RD, Ogawa K, Hatta A, Furuta H, Gaur N, Hong HS, Cowin A, Fukuhara H, Inoue K, Ito M, Charles C, Boswell RW, Bradley JW, Graves DB, Szili EJ.
    How plasma induced oxidation, oxygenation, and de-oxygenation influences viability of skin cells.
    Appl. Phys. Lett. 109, 203701 (2016); doi: http://dx.doi.org/10.1063/1.4967880
  3. Inoue K, Matsuyama H, Fujimoto K, Hirao Y, Watanabe H, Ozono S, Oyama M, Ueno M, Sugimura Y, Shiina H, Mimata H, Azuma H, Nagase Y, Matsubara A, Ito MY, Shuin T. The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light–guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA). Photodiagnosis Photodyn Ther. 2016 Mar;13:91-6.
  4. Fujita H, Nagakawa K, Kobuchi H, Ogino T, Kondo Y, Inoue K, Shuin T, Utsumi T, Utsumi K, Sasaki J, Ohuchi H. Phytoestrogen suppresses efflux of the diagnostic marker protoporphyrin IX (PpIX) in lung carcinoma. Cancer Res 2016 Feb 2. pii: canres.1484.2015.
  5. Ashida S, Yamasaki I, Tamura K, Shimamoto T, Inoue K, Kariya S, Kobayashi K, Yamagami T,Shuin T. Feasibility and early outcome of high-dose-rate Ir-192 brachytherapy as monotherapy in two fractions within 1 day for high-/very high-risk prostate cancer. Mol Clin Oncol 4 (5): 789-793, 2016.
  6. Nakayama T, Otsuka S, Kobayashi T, Okajima H, Matsumoto K, Hagiya Y, Inoue K, Shuin T, Nakajima M, Tanaka T, Ogura SI. Dormant cancer cells accumulate high protoporphyrin IX levels and are sensitive to 5-aminolevulinic acid-based photodynamic therapy. Sci Rep. 2016 Nov 18;6:36478.
  7. Obara W, Karashima T, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, Inoue K, Katagiri T, Shuin T, Nakamura Y, Fujioka T. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016 Oct 18.
  8. Taniguchi Y, Nishikawa H, Karashima T, Yoshinaga Y, Fujimoto S, Terada Y. Frequency of reactive arthritis, uveitis, and conjunctivitis in Japanese patients with bladder cancer following intravesical BCG therapy: A 20-year, two-centre retrospective study. Joint Bone Spine. 2016 Nov 4. pii: S1297-319X(16)30169-5.
  9. Taguchi T, Karashima T, Terada Y. Adrenal and thyroid metachronous metastases from renal cell carcinoma. Endocrine. 2016 Jul;53(1):335-6.
  10. Tamura K, Hazama S, Yamaguchi R, Imoto S, Takenouchi H, Inoue Y, Kanekiyo S, Shindo Y, Miyano S, Nakamura Y, Kiyotani K..Characterization of T cell repertoire in tumor tissues and blood in advanced colorectal cancers through deep T cell receptor sequencing. Oncol Lett. 2016 Jun;11(6):3643-3649.
  11. Nakakido M, Tamura K, Suyoun C, Ueda K, Kiyotani K, Nakamura Y. Phosphatidylinositol glycan anchor biosynthesis, class X containing complex promotes cancer cell proliferation through suppression of EHD2 and ZIC1, putative tumor suppressors Int J Oncol. 2016 Sep;49(3):868-76.
  12. Chapman CG, Yamaguchi R, Tamura K, Weidner J, Imoto S, Kwon J, Fang H, Yew PY, Marino SR, Miyano S, Nakamura Y, Kiyotani K. Characterization of T Cell Receptor Repertoire in Inflamed Tissues of Crohn’s Disease through Deep Sequencing. Inflamm Bowel Dis. 2016 Jun;22(6):1275-85.
  13. Ikeda Y, Kiyotani K, Yew PY, Kato T, Tamura K, Yap KL, Nielsen S, Mester J, Eng C, Nakamura Y, Grogan RH. Germline PARP4 mutations in patients with primary thyroid and breast cancers. Endocr Relat Cancer. 2016 Mar;23(3):171-9.
  14. Inoue H, Kato T, Olugbile S, Tamura K, Chung S, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y, Park JH. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget. 2016 Mar 22;7(12):13621-33.
  15. Oh JS, Short RD, Ogawa K, Hatta A, Furuta H, Gaur N, Hong SH, Cowin AJ, Fukuhara H, Inoue K, Ito M, Charles C, Boswell RW, Bradley JW, Graves DB, Szill EJ. How plasma induced oxidation, oxygenation, and de-oxygenation influences viability of skin cells. Appl Phys Lett 109, 203701-5, 2016
  16. Shimamoto T, Inoue K, Kamata M, Kuno T, Karashima T, Shuin T.
    Pathological risk factors in upper urinary tract cancer.
    Asia Pac J Clin Oncol. 2016;12(1):e179-88.

<和文> 10論文

  1. 蘆田真吾、井上啓史、執印太郎: 前立腺癌の浸潤・転移に関する分子, Ⅵ.前立腺癌の浸潤・転移, 新前立腺癌学 ― 最新の基礎研究と診断・治療 ― 日本臨牀 74巻 増刊号3, 2016.
  2. 小倉俊一郎、井上啓史:5-アミノレブリン酸を用いたがんの光線力学診療. 医学のあゆみ 258 (11) 1054-1057, 2016.
  3. 間 久直、本多典広、福原秀雄、井上啓史、執印太郎、倉林 睦、降幡睦夫、津田雅之、石井琢也、山内視嗣、村上清隆、井上克司、石塚昌宏、田中 徹、粟津邦男. 緑または赤色発光ダイオードによる光線力学治療のシミュレーションでの比較. レーザー研究 44 (3): 187-192, 2016
  4. 福原秀雄、井上啓史. 泌尿器領域におけるALA-PDD. 光アライアンス 27 (11): 40-43, 2016.
  5. 井上啓史. 経尿道的膀胱腫瘍切除術ってどんな手術?泌尿器Care&Cure URO-LO 21 (4): 36-39, 2016
  6. 刑部博人、田村賢司、山﨑一郎、深田 聡、蘆田真吾、弘井 誠、谷村正信、井上啓史、執印太郎. 放射線治療が奏功した前立腺未分化癌の1例. 泌尿器科紀要, 62(11):599-604, 2016
  7. 繁田正信、岩本秀雄、田村賢司
    血管処理の注意点と出血対処法:腎部分切除術-周術期合併症をいかに防ぐか?
    臨床泌尿器科 第70巻 第11号 856-860
  8. 甲田俊太郎、小羽田悠貴、内藤美季、岩本秀雄、田村賢司、繁田正信
    呉医療センター・中国がんセンター泌尿器科における腹腔鏡下前立腺全摘除術の長期成績Japanese journal of Endourology (2016) 29:185-191
  9. 山本新九郎、清水翔吾、井上啓史、齋藤源顕. 糖尿病と下部尿路症状. 排尿障害プラクティス Vol 24 No.1, 45-51, 2016.
  10. 辛島尚、執印太郎. 泌尿器とIgG4関連疾患. 別冊BIO Clinica. 5(4):60-65, 2016.
ホーム講座紹介卒前教育卒後研修診 療研 究業 績医局員募集リンクお問い合わせ